Table 1 Baseline characteristics and differences between patients with and without events in the follow-up
All patients | Event free (n = 320) | With events (n = 56) | P Value* | |
|---|---|---|---|---|
ANTHROPOMETRY | ||||
Age (y) | 64 ± 11 | 63 ± 11 | 68 ± 10 | 0.003 |
Sex (m) | 292 (78%) | 248 (76%) | 44 (79%) | 0.859 |
Body mass index | 26 ± 4 | 26 ± 4 | 26 ± 4 | 0.300 |
CAD RISK FACTORS | ||||
Familiar history of CAD | 170 (45%) | 143 (45%) | 27 (48%) | 0.625 |
Smoking habit | 220 (59%) | 179 (56%) | 41 (73%) | 0.015 |
Diabetes | 77 (21%) | 66 (21%) | 11 (20%) | 0.867 |
Hypertension | 218 (58%) | 185 (58%) | 33 (59%) | 0.876 |
Hypercholesterolemia | 214 (57%) | 181 (57%) | 33 (59%) | 0.742 |
# risk factors | 2.4 ± 1.1 | 2.4 ± 1.1 | 2.6 ± 1.1 | 0.159 |
CLINIC HISTORY | ||||
Previous CAD diagnosis | 332 (88%) | 277 (87%) | 55 (98%) | 0.012 |
Previous myocardial infarction | 246 (65%) | 202 (63%) | 44 (79%) | 0.025 |
NYHA classification (III class) | 22 (6%) | 11 (3%) | 11 (20%) | <0.0001 |
Revascularization in the follow-up | 79 (21%) | 73 (23%) | 6 (11%) | 0.040 |
PHARMACOLOGICAL THERAPY | ||||
β-blockers | 289 (77%) | 448 (78%) | 41 (73%) | 0.483 |
Ca++−antagonist | 76 (20%) | 62 (19%) | 14 (25%) | 0.334 |
Nitrates | 159 (42%) | 136 (43%) | 23 (41%) | 0.842 |
Loop diuretics | 135 (36%) | 95 (30%) | 40 (71%) | <0.0001 |
Aldosterone antagonist | 51 (14%) | 30 (9%) | 21 (38%) | <0.0001 |
ACE-inhibitors/AT1-receptors antagonist | 304 (81%) | 257 (80%) | 47 (84%) | 0.526 |
ASA | 319 (85%) | 275 (86%) | 44 (79%) | 0.156 |
Statins | 280 (75%) | 240 (75%) | 40 (71%) | 0.572 |
Anticoagulant | 33 (9%) | 18 (6%) | 15 (27%) | <0.0001 |
ECG | ||||
Heart rate (bpm) | 65 ± 13 | 64 ± 12 | 73 ± 14 | <0.0001 |
Non sinusal rhythm | 12 (3%) | 7 (2%) | 5 (9%) | 0.021 |
QRS duration (msec) | 105 ± 21 | 103 ± 19 | 112 ± 27 | 0.022 |
QTc interval (msec) | 425 ± 34 | 421 ± 32 | 447 ± 37 | <0.0001 |
LV hypertrophy | 58 (15%) | 50 (14%) | 8 (16%) | 0.942 |
LBB block | 59 (16%) | 44 (14%) | 15 (27%) | 0.013 |
RBB block | 16 (12%) | 12 (12%) | 4 (14%) | 0.612 |
ST segment depression | 46 (8%) | 38 (7%) | 8 (13%) | 0.176 |
Negative T waves | 184 (49%) | 151 (47%) | 33 (59%) | 0.105 |
Q waves | 164 (44%) | 135 (42%) | 29 (52%) | 0.181 |
ECHOCARDIOGRAPHY | ||||
LV EDV (ml/m2) | 59 ± 22 | 57 ± 20 | 74 ± 30 | <0.0001 |
LV ESV (ml/m2) | 31 ± 20 | 28 ± 16 | 49 ± 28 | <0.0001 |
LV EF (%) | 51 ± 13 | 53 ± 12 | 39 ± 15 | <0.0001 |
LV WMSI | 1.4 ± 0.5 | 1.4 ± 0.4 | 1.9 ± 0.5 | <0.0001 |
LV mass (g) | 188 ± 59 | 186 ± 57 | 202 ± 70 | <0.0001 |
LV diastolic function (≥ pseudo-normal) | 44 (12%) | 25 (8%) | 19 (34%) | <0.0001 |
Mitral regurgitation (≥ moderate) | 56 (15%) | 36 (11%) | 20 (36%) | <0.0001 |
Pulmonary hypertension | 34 (9%) | 19 (6%) | 15 (27%) | <0.0001 |
RVIT dilatation | 17 (5%) | 12 (4%) | 5 (9%) | 0.085 |
RV dysfunction | 38 (10%) | 28 (9%) | 10 (18%) | 0.037 |
LATE GADOLINIUM ENHANCEMENT | ||||
Total burden (% of LV mass) | 13 ± 15 | 10 ± 12 | 28 ± 22 | <0.0001 |
Spatial extent (% of LV surface) | 22 ± 22 | 18 ± 19 | 42 ± 29 | <0.0001 |
Max transmural extent (% of wall thickness) | 55 ± 39 | 51 ± 39 | 73 ± 39 | <0.0001 |